242 related articles for article (PubMed ID: 23318540)
1. Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.
Schmitt M; Xu X; Hilgendorf I; Schneider C; Borchert K; Gläser D; Freund M; Schmitt A
Bone Marrow Transplant; 2013 Jul; 48(7):922-5. PubMed ID: 23318540
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
[TBL] [Abstract][Full Text] [Related]
5. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation.
Schmitt M; Publicover A; Orchard KH; Görlach M; Wang L; Schmitt A; Mani J; Tsirigotis P; Kuriakose R; Nagler A
Theranostics; 2014; 4(3):280-9. PubMed ID: 24505236
[TBL] [Abstract][Full Text] [Related]
6. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.
Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D
Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657
[TBL] [Abstract][Full Text] [Related]
8. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.
Schmitt M; Hoffmann JM; Lorenz K; Publicover A; Schmitt A; Nagler A
Vox Sang; 2016 Aug; 111(2):178-86. PubMed ID: 27509033
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T
Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301
[TBL] [Abstract][Full Text] [Related]
11. Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.
Becker P; Schwebig A; Brauninger S; Bialleck H; Luxembourg B; Schulz M; Tsamadou C; Wiesneth M; Reinhardt P; Mytilineos J; Seidl C; Gattu S; Kaliakina N; Singh P; Schrezenmeier H; Seifried E; Bonig H
Transfusion; 2016 Dec; 56(12):3055-3064. PubMed ID: 27633122
[TBL] [Abstract][Full Text] [Related]
12. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
13. Is split-dose better than single-dose? Results of Turkish Stem Cell Coordination Center (TURKOK) donors in the era of rising biosimilar G-CSF.
Pınar İE; Özkocaman V; Özkalemkaş F; Durgut H; Dakiki B; Ersal T; Gürsoy V; Yalçın C; Orhan B; Candar Ö; Ali R
J Clin Apher; 2022 Oct; 37(5):430-437. PubMed ID: 35689647
[TBL] [Abstract][Full Text] [Related]
14. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.
Andreola G; Babic A; Rabascio C; Negri M; Martinelli G; Laszlo D
Eur J Haematol; 2012 Feb; 88(2):154-8. PubMed ID: 21992403
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study.
Sato K; Ishiyama K; Aoki G; Maruyama H; Tsuji N; Tanabe M; Zaimoku Y; Sato H; Yamazaki H; Yamaguchi M; Takami A; Nakao S
Int J Hematol; 2019 Dec; 110(6):648-653. PubMed ID: 31542851
[TBL] [Abstract][Full Text] [Related]
17. Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis.
Hsu JW; Wingard JR; Logan BR; Chitphakdithai P; Akpek G; Anderlini P; Artz AS; Bredeson C; Goldstein S; Hale G; Hematti P; Joshi S; Kamble RT; Lazarus HM; O'Donnell PV; Pulsipher MA; Savani BN; Schears RM; Shaw BE; Confer DL
Biol Blood Marrow Transplant; 2015 Jan; 21(1):165-71. PubMed ID: 25316111
[TBL] [Abstract][Full Text] [Related]
18. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study.
Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F
Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K
BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
